



CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, March 13, 2020

In accordance with Article 226 of the recast Spanish Securities Market Act (*Ley del Mercado de Valores*), is hereby reported the following:

### **INSIDE INFORMATION**

Further to communication on Inside Information dated March 3, 2020 (registered number 82), the Company reports that the *in vitro* studies results of Aplidin® (plitidepsin) on the human coronavirus HCoV-229E, which has a multiplication and propagation mechanism very similar to Covid-19, have been positive with a potency of the nanomolar order. These studies have been carried out at the National Biotechnology Centre (Centro Nacional de Biotecnología) of the Spanish National Research Council (CSIC) by Dr Luis Enjuanes, Dr Isabel Solá and Dr Sonia Zúñiga.

These results confirm the hypothesis that the therapeutic target of Aplidin® (plitidepsin), which is EF1A, is key to the multiplication and spread of the virus.

Based on these data, Pharma Mar will contact regulatory authorities to analyse the possibilities of studies on patients infected with Covid-19.